Details of the Drug

General Information of Drug (ID: DM0DXA8)

Drug Name
Droperidol
Synonyms
DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
Indication
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [1]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 379.4
Logarithm of the Partition Coefficient (xlogp) 3.5
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Bioavailability
75% of drug becomes completely available to its intended biological destination(s) [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.92 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 134 +/- 13 minutes (in adults), and 101.5 +/- 26.4 minutes (in children) [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.41 L/kg [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Tardive dyskinesia Not Available DRD2 OTBLXKEG [4]
Tardive dyskinesia Not Available DRD3 OT0OFFKB [4]
Tardive dyskinesia Not Available DRD4 OTAJTO7N [4]
Chemical Identifiers
Formula
C22H22FN3O2
IUPAC Name
3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
Canonical SMILES
C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
InChI
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
InChIKey
RMEDXOLNCUSCGS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3168
ChEBI ID
CHEBI:4717
CAS Number
548-73-2
DrugBank ID
DB00450
TTD ID
D03CJL
VARIDT ID
DR00771
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Binder [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Drug Response [4]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Drug Response [4]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Drug Response [4]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Nausea
ICD Disease Classification MD90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Droperidol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Droperidol and Metoclopramide. Nausea/vomiting [MD90] [7]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Droperidol and Granisetron. Nausea/vomiting [MD90] [8]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Droperidol and Dolasetron. Nausea/vomiting [MD90] [8]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Droperidol and Ondansetron. Nausea/vomiting [MD90] [8]
Coadministration of a Drug Treating the Disease Different from Droperidol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Droperidol and Ivosidenib. Acute myeloid leukaemia [2A60] [9]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Droperidol and Idarubicin. Acute myeloid leukaemia [2A60] [8]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Droperidol and Daunorubicin. Acute myeloid leukaemia [2A60] [8]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Droperidol and Arn-509. Acute myeloid leukaemia [2A60] [8]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Droperidol and Gilteritinib. Acute myeloid leukaemia [2A60] [8]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Droperidol and Oliceridine. Acute pain [MG31] [10]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Galantamine. Alzheimer disease [8A20] [8]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Rivastigmine. Alzheimer disease [8A20] [8]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Donepezil. Alzheimer disease [8A20] [8]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Droperidol and Metronidazole. Amoebiasis [1A36] [11]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Ivabradine. Angina pectoris [BA40] [12]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Droperidol and Bepridil. Angina pectoris [BA40] [8]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Droperidol and Dronedarone. Angina pectoris [BA40] [8]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Droperidol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [8]
Clorazepate DMC3JST Major Additive cardiorespiratory depression effects by the combination of Droperidol and Clorazepate. Anxiety disorder [6B00-6B0Z] [8]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Droperidol and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [8]
Halazepam DMPFWO6 Major Increased risk of prolong QT interval by the combination of Droperidol and Halazepam. Anxiety disorder [6B00-6B0Z] [8]
Oxazepam DMXNZM4 Major Additive cardiorespiratory depression effects by the combination of Droperidol and Oxazepam. Anxiety disorder [6B00-6B0Z] [8]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Droperidol and Cilostazol. Arterial occlusive disease [BD40] [8]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Droperidol and Voriconazole. Aspergillosis [1F20] [8]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Droperidol and Posaconazole. Aspergillosis [1F20] [8]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Levalbuterol. Asthma [CA23] [13]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Terbutaline. Asthma [CA23] [14]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Droperidol and Pirbuterol. Asthma [CA23] [14]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Droperidol and Salbutamol. Asthma [CA23] [15]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Droperidol and Formoterol. Asthma [CA23] [14]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Droperidol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [8]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Droperidol and Desipramine. Attention deficit hyperactivity disorder [6A05] [8]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Droperidol and Ofloxacin. Bacterial infection [1A00-1C4Z] [8]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Droperidol and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [8]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Droperidol and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [8]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Droperidol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [16]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Droperidol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [8]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Droperidol and Norfloxacin. Bacterial infection [1A00-1C4Z] [8]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Droperidol and Levofloxacin. Bacterial infection [1A00-1C4Z] [8]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Droperidol caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Droperidol and Lomefloxacin. Bacterial infection [1A00-1C4Z] [8]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Droperidol and Telithromycin. Bacterial infection [1A00-1C4Z] [8]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Droperidol and Retigabine. Behcet disease [4A62] [8]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Droperidol caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [18]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Droperidol and Loperamide. Bowel habit change [ME05] [19]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Droperidol and Eribulin. Breast cancer [2C60-2C6Y] [8]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Droperidol and Lapatinib. Breast cancer [2C60-2C6Y] [8]
Tucatinib DMBESUA Moderate Decreased metabolism of Droperidol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [17]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Droperidol and Tamoxifen. Breast cancer [2C60-2C6Y] [8]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Droperidol and Toremifene. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Droperidol and Bosutinib. Breast cancer [2C60-2C6Y] [8]
Mannitol DMSCDY9 Major Increased risk of prolong QT interval by the combination of Droperidol and Mannitol. Bronchiectasis [CA24] [8]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Droperidol and Sotalol. Cardiac arrhythmia [BC9Z] [8]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Droperidol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [8]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Olodaterol. Chronic obstructive pulmonary disease [CA22] [14]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Vilanterol. Chronic obstructive pulmonary disease [CA22] [13]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Salmeterol. Chronic obstructive pulmonary disease [CA22] [14]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Droperidol and Indacaterol. Chronic obstructive pulmonary disease [CA22] [14]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Arformoterol. Chronic obstructive pulmonary disease [CA22] [14]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Droperidol and Oxaliplatin. Colorectal cancer [2B91] [8]
Panitumumab DMQPD1F Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Panitumumab. Colorectal cancer [2B91] [8]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Isoproterenol. Conduction disorder [BC63] [14]
Desflurane DM2TO9R Major Increased risk of prolong QT interval by the combination of Droperidol and Desflurane. Corneal disease [9A76-9A78] [8]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Droperidol and Halothane. Corneal disease [9A76-9A78] [8]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Droperidol and Propofol. Corneal disease [9A76-9A78] [20]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Droperidol and Sevoflurane. Corneal disease [9A76-9A78] [8]
Methoxyflurane DML0RAE Major Increased risk of prolong QT interval by the combination of Droperidol and Methoxyflurane. Corneal disease [9A76-9A78] [8]
Alfentanil DMVO0UB Major Additive hypotensive effects by the combination of Droperidol and Alfentanil. Corneal disease [9A76-9A78] [8]
Isoflurane DMY6T31 Major Increased risk of prolong QT interval by the combination of Droperidol and Isoflurane. Corneal disease [9A76-9A78] [8]
Remifentanil DMZTXCH Major Additive hypotensive effects by the combination of Droperidol and Remifentanil. Corneal disease [9A76-9A78] [8]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Droperidol and Probucol. Coronary atherosclerosis [BA80] [8]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Droperidol and Clofazimine. Crohn disease [DD70] [8]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Droperidol and Mifepristone. Cushing syndrome [5A70] [8]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Droperidol and Pasireotide. Cushing syndrome [5A70] [8]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Droperidol and Osilodrostat. Cushing syndrome [5A70] [8]
Ethanol DMDRQZU Major Increased risk of prolong QT interval by the combination of Droperidol and Ethanol. Cystitis [GC00] [8]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Droperidol and Sertraline. Depression [6A70-6A7Z] [8]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Droperidol and Trimipramine. Depression [6A70-6A7Z] [8]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Droperidol and Imipramine. Depression [6A70-6A7Z] [8]
Naloxone DM3FXMA Major Increased risk of prolong QT interval by the combination of Droperidol and Naloxone. Depression [6A70-6A7Z] [8]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Droperidol and Fluoxetine. Depression [6A70-6A7Z] [8]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Droperidol and Nortriptyline. Depression [6A70-6A7Z] [8]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Droperidol caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [17]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Droperidol and Escitalopram. Depression [6A70-6A7Z] [8]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Droperidol and Clomipramine. Depression [6A70-6A7Z] [8]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Droperidol and Trazodone. Depression [6A70-6A7Z] [8]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Droperidol and Amoxapine. Depression [6A70-6A7Z] [8]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Droperidol and Doxepin. Depression [6A70-6A7Z] [8]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Droperidol and Maprotiline. Depression [6A70-6A7Z] [8]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Droperidol and Esketamine. Depression [6A70-6A7Z] [11]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Droperidol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [21]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Droperidol and Deutetrabenazine. Dystonic disorder [8A02] [22]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Droperidol and Ingrezza. Dystonic disorder [8A02] [8]
Diazepam DM08E9O Major Additive cardiorespiratory depression effects by the combination of Droperidol and Diazepam. Epilepsy/seizure [8A61-8A6Z] [8]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Droperidol and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [8]
Ethacrynic acid DM60QMR Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Ethacrynic acid. Essential hypertension [BA00] [8]
Benzthiazide DMQWZ0H Major Increased risk of prolong QT interval by the combination of Droperidol and Benzthiazide. Essential hypertension [BA00] [8]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Droperidol and Solifenacin. Functional bladder disorder [GC50] [8]
Itraconazole DMCR1MV Moderate Decreased metabolism of Droperidol caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [17]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Droperidol and Ketoconazole. Fungal infection [1F29-1F2F] [8]
Amphotericin B DMTAJQE Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Amphotericin B. Fungal infection [1F29-1F2F] [8]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Droperidol and Cisapride. Gastro-oesophageal reflux disease [DA22] [8]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Droperidol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [8]
Acetazolamide DM1AF5U Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Acetazolamide. Glaucoma [9C61] [8]
Methazolamide DM7J2TA Major Increased risk of prolong QT interval by the combination of Droperidol and Methazolamide. Glaucoma [9C61] [8]
Dichlorphenamide DMH7IDQ Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Dichlorphenamide. Glaucoma [9C61] [8]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Droperidol and Brimonidine. Glaucoma [9C61] [23]
Chlorothiazide DMLHESP Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Chlorothiazide. Heart failure [BD10-BD1Z] [8]
Furosemide DMMQ8ZG Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Furosemide. Heart failure [BD10-BD1Z] [8]
Hydroflumethiazide DMVPUQI Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [8]
Boceprevir DMBSHMF Moderate Decreased metabolism of Droperidol caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [17]
Telaprevir DMMRV29 Moderate Decreased metabolism of Droperidol caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [17]
Delavirdine DM3NF5G Moderate Decreased metabolism of Droperidol caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Droperidol caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Droperidol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [8]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Droperidol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Droperidol and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [24]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Droperidol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Droperidol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [8]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Droperidol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [8]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Droperidol caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Ritonavir DMU764S Moderate Decreased metabolism of Droperidol caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Fenoldopam DMFAOKP Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Fenoldopam. Hypertension [BA00-BA04] [8]
Indapamide DMGN1PW Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Indapamide. Hypertension [BA00-BA04] [8]
Trichlormethiazide DMHAQCO Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Trichlormethiazide. Hypertension [BA00-BA04] [8]
Hydrochlorothiazide DMUSZHD Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Hydrochlorothiazide. Hypertension [BA00-BA04] [8]
Conivaptan DM1V329 Moderate Decreased metabolism of Droperidol caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [17]
Fludrocortisone DMUDIR8 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [8]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Droperidol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [26]
Flurazepam DMAL4G0 Major Increased risk of prolong QT interval by the combination of Droperidol and Flurazepam. Insomnia [7A00-7A0Z] [8]
Triazolam DMETYK5 Major Increased risk of prolong QT interval by the combination of Droperidol and Triazolam. Insomnia [7A00-7A0Z] [8]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Droperidol and Quazepam. Insomnia [7A00-7A0Z] [8]
Estazolam DMZGXUM Major Additive cardiorespiratory depression effects by the combination of Droperidol and Estazolam. Insomnia [7A00-7A0Z] [8]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Polyethylene glycol. Irritable bowel syndrome [DD91] [27]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Phenolphthalein. Irritable bowel syndrome [DD91] [8]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Droperidol and Crizotinib. Lung cancer [2C25] [28]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Droperidol and Ceritinib. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Droperidol and Osimertinib. Lung cancer [2C25] [8]
Capmatinib DMYCXKL Moderate Decreased metabolism of Droperidol caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [29]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Droperidol and Selpercatinib. Lung cancer [2C25] [8]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Droperidol and Lumefantrine. Malaria [1F40-1F45] [11]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Droperidol and Halofantrine. Malaria [1F40-1F45] [30]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Droperidol and Chloroquine. Malaria [1F40-1F45] [8]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Droperidol and Hydroxychloroquine. Malaria [1F40-1F45] [8]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Droperidol and Quinine. Malaria [1F40-1F45] [8]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Droperidol and Primaquine. Malaria [1F40-1F45] [8]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Droperidol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [8]
Idelalisib DM602WT Moderate Decreased metabolism of Droperidol caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [17]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Droperidol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [31]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Droperidol and Vemurafenib. Melanoma [2C30] [8]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Droperidol and LGX818. Melanoma [2C30] [8]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Droperidol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [32]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Droperidol and Lasmiditan. Migraine [8A80] [33]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Droperidol and Flibanserin. Mood disorder [6A60-6E23] [34]
Midazolam DMXOELT Major Additive hypotensive effects by the combination of Droperidol and Midazolam. Mood/affect symptom [MB24] [8]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Droperidol and Panobinostat. Multiple myeloma [2A83] [35]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Droperidol and Thalidomide. Multiple myeloma [2A83] [11]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Siponimod. Multiple sclerosis [8A40] [11]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Ozanimod. Multiple sclerosis [8A40] [36]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Droperidol and Romidepsin. Mycosis fungoides [2B01] [8]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Droperidol and Dasatinib. Myeloproliferative neoplasm [2A20] [8]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Droperidol and Entrectinib. Non-small cell lung cancer [2C25] [8]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Droperidol and Lorcaserin. Obesity [5B80-5B81] [37]
Metolazone DMB39LO Major Increased risk of prolong QT interval by the combination of Droperidol and Metolazone. Oedema [MG29] [8]
Polythiazide DMCH80F Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Polythiazide. Oedema [MG29] [8]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Droperidol and Levomethadyl Acetate. Opioid use disorder [6C43] [12]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Droperidol and Lofexidine. Opioid use disorder [6C43] [8]
Nalmefene DM4YWCZ Major Increased risk of prolong QT interval by the combination of Droperidol and Nalmefene. Opioid use disorder [6C43] [8]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Droperidol and Apraclonidine. Optic nerve disorder [9C40] [23]
Rofecoxib DM3P5DA Moderate Decreased metabolism of Droperidol caused by Rofecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [17]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Droperidol and Rucaparib. Ovarian cancer [2C73] [8]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Droperidol and Dextropropoxyphene. Pain [MG30-MG3Z] [38]
Butorphanol DM5KYPJ Major Increased risk of prolong QT interval by the combination of Droperidol and Butorphanol. Pain [MG30-MG3Z] [8]
Oxymorphone DM65AGJ Major Increased risk of prolong QT interval by the combination of Droperidol and Oxymorphone. Pain [MG30-MG3Z] [8]
Levorphanol DMGS80V Major Increased risk of prolong QT interval by the combination of Droperidol and Levorphanol. Pain [MG30-MG3Z] [8]
Dezocine DMJDB0Y Major Increased risk of prolong QT interval by the combination of Droperidol and Dezocine. Pain [MG30-MG3Z] [8]
Nalbuphine DMOSQGU Major Increased risk of prolong QT interval by the combination of Droperidol and Nalbuphine. Pain [MG30-MG3Z] [8]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Droperidol and Buprenorphine. Pain [MG30-MG3Z] [8]
Meperidine DMX4GND Major Additive hypotensive effects by the combination of Droperidol and Meperidine. Pain [MG30-MG3Z] [8]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Droperidol caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [17]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Droperidol and Triclabendazole. Parasitic worm infestation [1F90] [8]
Pergolide DM14MAE Moderate Antagonize the effect of Droperidol when combined with Pergolide. Parkinsonism [8A00] [39]
Opicapone DM1BKA6 Moderate Antagonize the effect of Droperidol when combined with Opicapone. Parkinsonism [8A00] [39]
Entacapone DMLBVKQ Moderate Antagonize the effect of Droperidol when combined with Entacapone. Parkinsonism [8A00] [39]
Levodopa DMN3E57 Moderate Additive CNS depression effects by the combination of Droperidol and Levodopa. Parkinsonism [8A00] [39]
Bromocriptine DMVE3TK Moderate Antagonize the effect of Droperidol when combined with Bromocriptine. Parkinsonism [8A00] [39]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Droperidol and Apomorphine. Parkinsonism [8A00] [8]
Abametapir DM2RX0I Moderate Decreased metabolism of Droperidol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [40]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Droperidol and Famotidine. Peptic ulcer [DA61] [11]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Droperidol and Macimorelin. Pituitary gland disorder [5A60-5A61] [41]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Droperidol and Lefamulin. Pneumonia [CA40] [42]
Hydrocortisone DMGEMB7 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Hydrocortisone. Postoperative inflammation [1A00-CA43] [8]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Droperidol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [17]
Ritodrine DM4V6RL Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Ritodrine. Preterm labour/delivery [JB00] [14]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Droperidol and Degarelix. Prostate cancer [2C82] [8]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Droperidol and ABIRATERONE. Prostate cancer [2C82] [8]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Droperidol and Nilutamide. Prostate cancer [2C82] [8]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Droperidol and Enzalutamide. Prostate cancer [2C82] [8]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Droperidol and Flutamide. Prostate cancer [2C82] [8]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Droperidol and Relugolix. Prostate cancer [2C82] [8]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Droperidol and Bicalutamide. Prostate cancer [2C82] [8]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Droperidol and Levomepromazine. Psychotic disorder [6A20-6A25] [8]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Droperidol and Fluphenazine. Psychotic disorder [6A20-6A25] [8]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Droperidol and Triflupromazine. Psychotic disorder [6A20-6A25] [8]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Droperidol and Gatifloxacin. Respiratory infection [CA07-CA4Z] [8]
Neupro DMHEAB1 Moderate Antagonize the effect of Droperidol when combined with Neupro. Restless legs syndrome [7A80] [39]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Droperidol and Quetiapine. Schizophrenia [6A20] [8]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Droperidol and Mesoridazine. Schizophrenia [6A20] [8]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Droperidol and Thioridazine. Schizophrenia [6A20] [8]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Droperidol and Iloperidone. Schizophrenia [6A20] [8]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Droperidol and Paliperidone. Schizophrenia [6A20] [8]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Droperidol and Haloperidol. Schizophrenia [6A20] [8]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Droperidol and Perphenazine. Schizophrenia [6A20] [8]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Droperidol and Chlorpromazine. Schizophrenia [6A20] [43]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Droperidol and Trifluoperazine. Schizophrenia [6A20] [8]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Droperidol and Risperidone. Schizophrenia [6A20] [8]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Droperidol and Amisulpride. Schizophrenia [6A20] [44]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Droperidol and Asenapine. Schizophrenia [6A20] [8]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Droperidol and Pimozide. Schizophrenia [6A20] [12]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Droperidol and Fentanyl. Sensation disturbance [MB40] [8]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Droperidol and Vardenafil. Sexual dysfunction [HA00-HA01] [8]
Larotrectinib DM26CQR Moderate Decreased metabolism of Droperidol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Droperidol and LEE011. Solid tumour/cancer [2A00-2F9Z] [8]
Cisplatin DMRHGI9 Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [8]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Droperidol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [8]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Droperidol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [8]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Droperidol and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [8]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Droperidol and Pitolisant. Somnolence [MG42] [8]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Droperidol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [8]
Naltrexone DMUL45H Major Increased risk of prolong QT interval by the combination of Droperidol and Naltrexone. Substance abuse [6C40] [8]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Droperidol and Adenosine. Supraventricular tachyarrhythmia [BC81] [45]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Droperidol and Lenvatinib. Thyroid cancer [2D10] [8]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Droperidol and Cabozantinib. Thyroid cancer [2D10] [8]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Droperidol and Papaverine. Tonus and reflex abnormality [MB47] [46]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Droperidol and Tizanidine. Tonus and reflex abnormality [MB47] [8]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Droperidol and Tacrolimus. Transplant rejection [NE84] [8]
Enoxacin DMYTE6L Moderate Decreased metabolism of Droperidol caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [17]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Droperidol and Astemizole. Vasomotor/allergic rhinitis [CA08] [8]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Droperidol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [8]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Droperidol and Procainamide. Ventricular tachyarrhythmia [BC71] [8]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Droperidol and Propafenone. Ventricular tachyarrhythmia [BC71] [8]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Droperidol and Flecainide. Ventricular tachyarrhythmia [BC71] [8]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Droperidol and Amiodarone. Ventricular tachyarrhythmia [BC71] [8]
⏷ Show the Full List of 240 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7172).
2 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.
6 Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):130-40. doi: 10.1016/j.vascn.2006.03.011. Epub 2006 Apr 25.
7 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
8 Canadian Pharmacists Association.
9 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
10 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
11 Cerner Multum, Inc. "Australian Product Information.".
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
14 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
15 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
16 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
17 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
18 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
20 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
21 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
22 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
23 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
24 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
25 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
26 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
27 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
28 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
29 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
30 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
31 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
32 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
33 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
34 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
35 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
37 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
38 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
39 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
40 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
41 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
42 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
43 Product Information. Inapsine (droperidol). Janssen Pharmaceutica, Titusville, NJ.
44 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
45 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
46 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]